Tania Gendron, PhD, speaks to the present challenges for translating biomarker discoveries to clinical practice and offers ...

Once daily treatment with Denali's oral candidate DNL343 failed to reduce NfL levels in adults with ALS in the HEALEY trial.

Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene ...

SDTC is a well-established electrophysiological biomarker of peripheral motor excitability related to ALS, where elevation of SDTC has been clinically shown to predict faster disease progression ...

Damaged muscles in ALS patients release proteins previously linked only to brain disease In a nutshell Researchers discovered ...